Doustne leki przeciwkrzepliwe niebędące antagonistami witaminy K (NOAC, non-vitamin K
antagonist oral anticoagulants) wymieniane są w wytycznych dotyczących leczenia …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. On average, it entails a two-
fold increase in risk of all-cause mortality, and a five-fold increase in risk of stroke. Oral …

Cardiovascular diseases can affect the clinical course of coronavirus disease 2019 (COVID-
19); however, evaluation of COVID-19 contribution to prognosis for each individual disease …

Background: Off-label dosing of direct oral anticoagulants (DOAC) as a treatment for non-
valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of …

Atrial fibrillation (AF) and stroke are two prevalent health conditions with many shared risk
factors. Over the past two decades, non-vitamin K antagonist oral anticoagulants (NOACs) …

Background: The very elderly (≥ 80 years) are at high risk of nonvalvular atrial fibrillation
(NVAF) and thromboembolism, as older age represents the most prominent risk factor for …

Dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention
(PCI) has been established as the standard therapy. In Korean patients, low response of …

Introduction: Despite the rise of direct oral anticoagulants (DOACs), vitamin K antagonists
(VKA) remain the most widely used oral anticoagulants in developing countries. The aim of …

Background and purpose Renal excretion of direct oral anticoagulants (DOACs) varies
depending on the drug. Hypothetically, an increased glomerular filtration rate (GFR) may …

Oral anticoagulants (OACs) are among the most commonly used medication worldwide.
Vitamin K antagonists, such as warfarin, were the only available oral anticoagulants for over …